Business Wire

Study results demonstrate 74% reduction in surgical site infections with use of PICO™ Single use Negative Pressure Wound Therapy system

Del

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, proudly supports results of an independent, randomised clinical trial1 concluding that, in the patients studied, the use of the PICO Single Use Negative Pressure Wound Therapy (NPWT) system significantly reduced the rate of surgical site infections (SSI) by 74%, compared to standard care in patients undergoing major abdominal incisions.

The randomized, controlled, open-label trial of 50 patients investigated the role of PICO Single Use NPWT used prophylactically in patients undergoing major abdominal surgery. Thirty days after operations, the incidence rates of SSI significantly reduced by 74% (8.3% in treatment group vs. 32% in control group). Patients’ length of stay also reduced by approximately eight days (6.1 vs. 14.7 days). The treatment group included the use of the PICO Single Use NPWT system.

The PICO Single Use NPWT system is indicated for patients at risk of poor healing as it can help to improve the speed, strength and quality of incisional wound closure, and may minimise the failures of healing that may lead to infection and/or dehiscence2. The PICO system is suitable for use in both a hospital and community setting and approved for a number of indications, including surgically closed incision sites.

“This study underscores the importance of PICO Single Use NPWT in treating patients who have undergone a laparotomy (open abdominal surgery),” said Colin Peirce, Consultant General and Colorectal Surgeon, University Hospital Limerick, Ireland. “As surgeons, we are always looking for effective and cost efficient ways to treat patients, and this study demonstrates that PICO Single Use NPWT can significantly reduce both the incidence of surgical site infection and the length of stay, resulting in a potential reduction in healthcare costs,” concludes Colin Pierce.

Up to 60% of all SSIs are preventable but they continue to be a large burden on the healthcare system3. With approximately 500,000 SSIs per year in the US and 8,000 connected annual deaths, the cost of SSIs are in excess of $7 billion and over £758 million per year in the UK3.

“This study is the latest addition of research that reinforces the importance of PICO Single Use NPWT and the significant impact it has on reducing SSIs, healthcare costs and ultimately improving the patient’s quality of life,” said Andy Weymann, Chief Medical Officer in Smith & Nephew. “It follows the recent release of global guidelines from the World Health Organisation (WHO) recommending the use of NPWT prophylactically,” added Andy Weymann.

The PICO Single Use NPWT system is being investigated in a number of clinical trials worldwide. For more information about the clinical trials, please visit: www.clinicaltrials.gov.

- Ends -

™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office

About Negative Pressure Wound Therapy (NPWT)

Negative Pressure Wound Therapy (NPWT) has been in use for more than 20 years for the management of a wide range of different wound types in adults, including traumatic hard-to-heal and chronic wounds, and wounds covered with flaps and/or skin grafts. It has also been used for the management of complex wounds. More recently, NPWT systems have been used to manage closed surgical incisions in patients at high risk of surgical site complications.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

To learn more about what we do to help reduce surgical site complications, please visit www.closertozero.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

Reference:

1. O’Leary, D.P. et al, Prophylactic negative pressure dressing use in closed laparotomy wounds following abdominal operations. A randomized, controlled, open-label trial: The PICO Trial. Annals of Surgery, published online 06 December 2016.

2. S. Karlakki, M. Brem, S. Giannini, V. Khanduja, J. Stannard, R. Martin. Negative pressure wound therapy for management of the surgical incision in orthopaedic surgery. Bone Joint Res 2013;2:276–84.

3. World Union of Wound Healing Societies (WUWHS) Consensus Document. Closed surgical incision management: understanding the role of NPWT. Wounds International, 2016

Contact information

Madano
Karley Ura
+44 (0) 20 3595 2415
or
Jaclyn Confalone
+44 (0) 20 3595 2441
or
Smith & Nephew
Dave Snyder
+1 (978) 749-1440

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00Pressemelding

Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu

World Trade Center Gibraltar: £65m Annual Boost to Local Economy20.10.2017 09:48Pressemelding

A report detailing the social and economic impacts of World Trade Center (WTC) Gibraltar was presented to the World Trade Centers Association (WTCA) in New York this week. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005285/en/ Ed Allison-Wright of WTC Gibraltar, with Scott Ferguson, WTCA, New York (Photo: Business Wire) Following the official opening of World Trade Center Gibraltar by the Chief Minister and Deputy Chief Minister in February of this year, World Trade Center Gibraltar commissioned the independent international economic consultancy Nairne Limited, to study and report on the economic contributions of the World Trade Center to the Gibraltar economy. This comes in the midst of an unprecedented take up of the office accommodation within the state-of-the-art facility. An astonishing

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom